Skip to main content
main-content

01.06.2014 | Original Article - Clinical Oncology | Ausgabe 6/2014

Journal of Cancer Research and Clinical Oncology 6/2014

The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 6/2014
Autoren:
Yun Zhang, Jiaqi Dai, Tingting Wu, Nailin Yang, Zhiqiang Yin

Abstract

Purpose

Hashimoto’s thyroiditis (HT) is the most common type of autoimmune thyroid disease, and the incidence is rising in recent years. The aim of this study was to evaluate the pathological characteristics, treatment and prognosis of HT with papillary thyroid carcinoma (PTC).

Methods

From July 2004 to December 2011, 8,524 patients underwent thyroid surgery in our hospital and 1,735 patients were diagnosed with PTC. The data from these patients were statistically analyzed using SAS software.

Results

There were 839 patients with a final diagnosis of HT in this study. A greater incidence of PTC was found in those with HT (29.4 %) than those without HT (19.4 %; p < 0.05). Male HT patients had a significantly higher rate of PTC (27/61, 44.3 %) when compared to female patients (220/778, 28.3 %; p < 0.05). The HT patients with co-occurring PTC were more likely to be younger (43.1 vs. 46.6, p < 0.01) and had smaller nodules (1.10 vs. 1.34 cm, p < 0.05), less external invasion (0.4 vs. 2.5 %, p < 0.05), less lymph node metastasis in lateral neck area (17.2 vs. 26.9 %, p < 0.05) and less advanced TNM stages than PTC patients without HT.

Conclusions

Hashimoto’s thyroiditis is associated with a significantly higher risk of PTC, and the incidence of PTC is much higher in male HT patients. More attention should be paid to HT patients, especially male HT patients, for signs of PTC. Based on the less aggressive pathological features in HT–PTC group, we should not blindly expand the indication and extent of surgery.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2014

Journal of Cancer Research and Clinical Oncology 6/2014 Zur Ausgabe

Original Article – Clinical Oncology

Primary malignant cardiac tumors

  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise